India’s medicine market has a stronger sales headline. Reading it properly requires more than looking at the growth rate.
PharmaTrac data put sales at ₹70,180 crore in July to September 2026, up 12% from a year earlier. That followed growth of 11% in each of the preceding two quarters and 10% in October to December 2025.
These are increases in sales value. They are not equivalent to increases in the number of packs sold, patients treated or people developing a disease.
The Breakdown
A medicine market can grow in value through several routes: more units, different prices, a changing mix of products or a shift in which suppliers capture sales. The headline alone cannot tell us the contribution of each.
Industry specialists see chronic therapies as an important source of momentum, but caution that performance is not uniform across therapeutic categories or companies. The figures should also be read within the dataset’s coverage, rather than as a census of every manufacturer.
It would therefore be premature to turn the latest figures into a claim that all drugmakers are enjoying the same demand surge, or that stronger recorded sales establish a particular change in patients’ health.
One company shows why the definitions matter
Torrent Pharmaceuticals reported ₹2,181 crore of revenue from its base India business in the September quarter, up 20%. Its consolidated India revenue, including J.B. Chemicals & Pharmaceuticals, known as JB Pharma, was ₹2,861 crore, up 57%.
Those are not two conflicting accounts of the same performance. One separates the base business; the other includes the enlarged group. The company also reported 7% growth in JB’s India prescription business excluding trade generics and contrast media, showing that even businesses inside the same group can move at different speeds.
Torrent compared its base business with the same PharmaTrac market growth figure. That comparison does not create a second independent measurement of the entire market.
Why This Matters
For anyone reading a pharmaceutical company’s results, three questions should come before the conclusion: what period is being measured, which businesses are included, and is the figure about sales value or volume?
A business that acquires another company can become larger without achieving the same rate of expansion in its existing operations. Equally, a company can outperform an industry average because its product portfolio differs from the average. Neither situation makes the headline wrong; both make its definition essential.
For households, the relevant question is different again. A larger industry sales total does not establish that a recurring prescription has become more affordable. Affordability and availability need evidence about the medicines people actually buy, rather than an inference from company revenue.
The Crunch
The useful next test is not whether every pharmaceutical headline repeats double digit growth. It is whether the underlying figures explain how that growth was earned. Keep value, volume, portfolio and acquisition effects separate, and a much clearer picture of the medicine business emerges.
Related categories: Economy & Markets
Leave your thoughts